Cargando…

Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial

BACKGROUND: Molnupiravir is an orally administered antiviral authorized for COVID-19 treatment in adults at high risk of progression to severe disease. Here, we report secondary and post hoc analyses of participants’ self-reported symptoms in the MOVe-OUT trial, which evaluated molnupiravir initiate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guan, Yanfen, Puenpatom, Amy, Johnson, Matthew G, Zhang, Ying, Zhao, Yujie, Surber, Joseph, Weinberg, Aaron, Brotons, Carlos, Kozlov, Roman, Lopez, Rudy, Coetzee, Kathleen, Santiaguel, Joel, Du, Jiejun, Williams-Diaz, Angela, Brown, Michelle, Paschke, Amanda, De Anda, Carisa, Norquist, Josephine M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686947/ https://www.ncbi.nlm.nih.gov/pubmed/37466374 http://dx.doi.org/10.1093/cid/ciad409

Ejemplares similares

Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial
por: Johnson, Matthew G., et al.
Publicado: (2023)

Making Statistical Sense of the Molnupiravir MOVe-OUT Clinical Trial
por: Thorlund, Kristian, et al.
Publicado: (2022)

511. Treatment with Molnupiravir in the MOVe-In and MOVe-Out Clinical Trials Results in an Increase in Transition Mutations Across the SARS-CoV-2 Genome
por: Strizki, Julie, et al.
Publicado: (2021)

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
por: Jayk Bernal, Angélica, et al.
Publicado: (2021)

Potential Anti-Mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and Their Potential Use as Treatments
por: Akazawa, Daisuke, et al.
Publicado: (2023)

Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis
por: Martin-Loeches, Ignacio, et al.
Publicado: (2023)

Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial
por: Campillo, Jérémy T, et al.
Publicado: (2021)

Saccharomyces boulardii to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial
por: Ehrhardt, Stephan, et al.
Publicado: (2016)

Effect of Inadequate Empiric Antibacterial Therapy on Hospital Outcomes in SARS-CoV-2-Positive and -Negative US Patients With a Positive Bacterial Culture: A Multicenter Evaluation From March to November 2020
por: Puzniak, Laura, et al.
Publicado: (2021)

A Randomized, Placebo-Controlled Trial Assessing the Effect of VISBIOME ES Probiotic in People With HIV on Antiretroviral Therapy
por: Presti, Rachel M, et al.
Publicado: (2021)

Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
por: Goswami, Hardik, et al.
Publicado: (2022)

Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials
por: Hayden, Frederick G, et al.
Publicado: (2022)

Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
por: Goswami, Hardik, et al.
Publicado: (2023)

Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial
por: Zhao, Ying, et al.
Publicado: (2023)

Duvelisib for Critically Ill Patients With Coronavirus Disease 2019: An Investigator-Initiated, Randomized, Placebo-Controlled, Double-Blind Pilot Trial
por: Goldsmith, Scott R, et al.
Publicado: (2023)

Staphylococcus aureus Infections After Elective Cardiothoracic Surgery: Observations From an International Randomized Placebo-Controlled Trial of an Investigational S aureus Vaccine
por: Allen, Keith B., et al.
Publicado: (2014)

Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
por: Holubar, Marisa, et al.
Publicado: (2022)

A Phase 2, Randomized, Multicenter, Placebo-Controlled, Proof-of-Concept Trial of Oral Fexinidazole in Adults With Chronic Indeterminate Chagas Disease
por: Torrico, Faustino, et al.
Publicado: (2022)

The STOP COVID 2 Study: Fluvoxamine vs Placebo for Outpatients With Symptomatic COVID-19, a Fully Remote Randomized Controlled Trial
por: Reiersen, Angela M, et al.
Publicado: (2023)

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
por: Heath, Paul T, et al.
Publicado: (2022)

Evaluation of Renal Safety Between Imipenem/Relebactam and Colistin Plus Imipenem in Patients With Imipenem-Nonsusceptible Bacterial Infections in the Randomized, Phase 3 RESTORE-IMI 1 Study
por: Brown, Michelle L, et al.
Publicado: (2020)

A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy
por: O’Brien, Meagan P., et al.
Publicado: (2017)

Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial( )
por: Middleton, Bianca F, et al.
Publicado: (2022)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection
por: Lim, Jeremy J, et al.
Publicado: (2021)

Effect of Swine Glyco-humanized Polyclonal Neutralizing Antibody on Survival and Respiratory Failure in Patients Hospitalized With Severe COVID-19: A Randomized, Placebo-Controlled Trial
por: Gaborit, Benjamin, et al.
Publicado: (2023)

Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)

Computational Analysis of Molnupiravir
por: Sharov, Artem V., et al.
Publicado: (2022)

Molnupiravir for COVID-19
Publicado: (2022)

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
por: Streinu-Cercel, Anca, et al.
Publicado: (2022)

Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial( )
por: ten Doesschate, Thijs, et al.
Publicado: (2021)

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load
por: Dougan, Michael, et al.
Publicado: (2021)

Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
por: Ison, Michael G, et al.
Publicado: (2023)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial
por: Chen, Peter, et al.
Publicado: (2022)

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial
por: Khoo, Saye H, et al.
Publicado: (2023)

A Decade On: Systematic Review of ClinicalTrials.gov Infectious Disease Trials, 2007–2017
por: Jaffe, Ian S, et al.
Publicado: (2019)

Contribution of Serologic Assays in the Evaluation of Influenza Virus Infection Rates and Vaccine Efficacy in Pregnant Women: Report From Randomized Controlled Trials
por: Madhi, Shabir A., et al.
Publicado: (2017)

A Randomized Clinical Trial of Transgender Women Switching to B/F/TAF: The (mo)BETTA Trial
por: Lake, Jordan E, et al.
Publicado: (2023)

Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial
por: Iroh Tam, Py, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_2khlo7p86j3qdej1aumg92eqog